MARTINSRIED, Germany, May 18, 2006 (PRIMEZONE) -- MorphoSys AG (Frankfurt:MOR) (Prime Standard Segment:TecDAX) announced today that at the Company's annual shareholder meeting on Wednesday, May 17, 2006, its shareholders confirmed the reappointment of Prof. Dr. Jurgen Drews and Prof. Dr. Andreas Pluckthun to the Supervisory Board. Prof. Drews, Managing Director of the Bear Stearns Health Innoventure Fund, has been a member of the MorphoSys Supervisory Board since 1997, and also holds the position of Deputy Chairman. Prof. Pluckthun, Professor for Biochemistry at the University of Zurich, Switzerland, is a co-founder of MorphoSys.
In addition to the confirmation of the appointment of Prof. Drews and Prof. Pluckthun to the Supervisory Board, all other management proposals to the shareholder assembly agenda were passed with large majorities at the meeting, which took place in Munich.
"We are very happy that Professor Drews and Professor Pluckthun have been reappointed to our board and look forward to continue working with them," commented Dr. Simon Moroney, Chief Executive Officer of MorphoSys AG. "Their commitment and enormous contributions to MorphoSys's successful development over the last several years has been extremely valuable for the Company."
Attachments:
http://hugin.info/130295/R/1051741/174428.pdf
About MorphoSys:
MorphoSys develops and applies innovative technologies for the production of synthetic antibodies, which accelerate drug discovery and target characterization. Founded in 1992, the Company's proprietary Human Combinatorial Antibody Library (HuCAL(R)) technology is used by researchers worldwide for human antibody generation. The Company currently has licensing agreements and/or research collaborations with Bayer (Berkeley, California/USA), Boehringer Ingelheim (Ingelheim, Germany), Bristol-Myers Squibb (New Jersey/USA), Centocor Inc. (Malvern, Pennsylvania/USA), Daiichi Sankyo & Co., Ltd. (Tokyo/Japan), GPC Biotech AG (Munich/Germany), Hoffmann-La Roche AG (Basel/Switzerland), ImmunoGen Inc. (Cambridge, Massachusetts/USA), Merck & Co., Inc. (Whitehouse Station, New Jersey/USA), Novartis AG (Basel, Switzerland), Novoplant GmbH (Gatersleben, Germany), Pfizer Inc. (Delaware/USA), ProChon Biotech Ltd. (Rehovot/Israel), Schering AG (Berlin/Germany), Schering-Plough (Palo Alto/USA), Shionogi & Co., Ltd. (Osaka/Japan), Xoma Ltd. (Berkeley, California/USA) and others. Additionally, MorphoSys is active in the antibody research market through its Antibodies by Design business unit. Antibodies by Design was founded in 2003 for the purpose of exploiting the MorphoSys non-therapeutic antibody markets. MorphoSys' activities in the research antibody segment were significantly strengthened through the acquisition of the U.K. and U.S.-based Biogenesis Group in January 2005 and Serotec Group in 2006. For further information please visit the corporate website at: http://www.morphosys.com/.
Statements included in this press release which are not historical in nature are intended to be, and are hereby identified as, "forward-looking statements" for purposes of the safe harbour provided by Section 21E of the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by words including "anticipates", "believes", "intends", "estimates", "expects" and similar expressions. The company cautions readers that forward-looking statements, including without limitation those relating to the company's future operations and business prospects, are subject to certain risks and uncertainties that could cause actual results to differ materially from those indicated in the forward-looking statements. Factors that may affect future operations and business prospects include, but are not limited to, clinical and scientific results and developments concerning corporate collaborations and the company's proprietary rights.